Opinions

Benefits of these targeted agents are not limited to tumours with germline BRCA1/2 mutations, but many questions remain to be answered

ctDNA offers immense possibilities for improving the management of early-stage lung cancer and the area is primed for new trials to test this approach in the context of minimal residual disease

Personalised proteogenomics has the power to transform the identification, staging and management of NSCLC in never smokers

Innovative models and increased cross-border collaborations can further support the implementation of rare cancer reference centres to expedite diagnosis and improve treatment

Research is ongoing to revisit the classic neoantigen approach that may better interpret the complexity of the immune system 

Evidence is compelling, but utility may depend on the clinical context

Addressing cost and affordability issues is now key to increasing the use of this approach in the clinical setting in Asia 

Recent studies show how digital health apps enhance the patient experience, and improve multiple quality of life domains and in some cases, adherence to treatment, but their integration into the healthcare system is still a challenge

Successful partnerships between industry and academia has had a positive impact on cancer drug discovery and development in prostate cancer

Digital tools offer potential solutions to personalise the patient journey, but more effort is needed to integrate them into current healthcare settings